BiotechTube
Home/Palvella Therapeutics/Matthew W. Gantz
MW

Matthew W. Gantz

Chief Financial Officer

Palvella Therapeutics

Therapeutic Areas

DermatologyRare Genetic Diseases

Palvella Therapeutics Pipeline

DrugIndicationPhase
QTORIN 3.9% Rapamycin Anhydrous GelPachyonychia Congenita (PC)Phase 3

Leadership Team at Palvella Therapeutics

WK
Wes Kaupinen
Founder, Chairman & CEO
RB
Robert Buck, PhD
Founder & Chief Scientific Officer
JT
Jay T. Backstrom, MD, MPH
Chief Medical Officer
PB
Patrick Burnett, MD, PhD
Chief Development Officer
View full Palvella Therapeutics profile